Drug Distribution and Control: Preparation and Handling
This Technical Assistance Bulletin is intended to assist pharmacists in the extemporaneous compounding of non-sterile drug products for individual patients. Included in this document is information on facilities and equipment, ingredient... selection, training, documentation and record keeping, stability and beyond-use dating, packaging and labeling, and limited batch compounding. This document is not intended for manufacturers or licensed repackagers.
more
Testing men for HIV during their partner’s pregnancy can guide couples-based HIV prevention and treatment, but testing rates remain low. We investigated a combination approach, using evidence-based strategies, to increase HIV testing in male partners of HIV-positive and HIV-negative ...pregnant women.
more
In order to streamline and effectively control compounding of medicinal products in hospitals and pharmacies, these Guidelines for Production of Extemporaneous and Hospital Based Sterile Preparations has been crafted. The purpose of these guidelines therefore is to assist pharmacists in ...discharging their legal and professional obligations to patients in the area of extemporaneous dispensing. This guidance will help to assure the safe and appropriate preparation and supply of extemporaneously prepared medicinal products to patients, where
the supply of such products is necessary.
Extemporaneous and hospital based sterile preparations are critical for patients whose clinical needs cannot be met by registered medicinal products. The guidelines outline the principles and application of the concepts of Good Manufacturing Practice (GMP) requirements for premises, equipment, personnel, storage, quality management system, quality control, compounding processes as well as documentation.
more
After completing this activity, pharmacists should be able to:
1. List populations for which the compounding of an oral liquid may be necessary
2. Outline necessary considerations that should be made by the pharmacist to ensure product stability
3. Describe methods used in the compounding of liqu...id preparations
more
J Pharm Pharm Sci (www.cspsCanada.org) 16(3) 441 - 455, 2013
Die aktuellen Leitlinien stellen detailliert und umfassend die gesamte wissen-
schaftliche Basis und die daraus abgeleiteten Therapieempfehlungen in elf Einzel-
kapiteln dar. Darunter befinden sich auch allgemeingültige Empfehlungen wie
zum Beispiel zur Ausbildung und zu ethischen Fragestellunge...n am Lebensende.
Um Ihnen einen möglichst schnellen und gleichzeitig umfassenden Überblick zu
ermöglichen, haben wir für Sie in diesem Taschenbuch die wesentlichen Aussagen
aus allen Kapiteln als Kurzfassung zusammengestellt.
more
The case for evidence- based communication of science
Apresentação do PLANO NACIONAL DE EXPANSÃO DA TESTAGEM PARA COVID-19 e orientações acerca dos dois
O Ministério da Saúde atualiza o Diagnosticar para Cuidar com o PLANO NACIONAL DE EXPANSÃO DA TESTAGEM PARA COVID-19 (PNE-Teste) que tem a finalidade de expandir o diagnóstico da covid-19 por meio do teste rápido de antígeno (TR-AG), para uso em indivíduos sintomáticos e assintomáticos, par...a monitorar a situação epidemiológica e direcionar os esforços desta Pasta ministerial na contenção da pandemia no território nacional.
more
24 Nov. 2021; This guidance provides considerations and a series of options that can be used to inform country strategies to minimise risk associated with shortages of personal protective equipment (PPE).
Re-use and reprocessing of single use PPE must be a last-resort temporary measure that is impl...emented only until stocks are replenished (2).This remains an area of active research and further updates to this evidence base are anticipated.
more
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian...ts; and (iv) how populations understand these dynamics, perceive risk and follow control measures, including public health and social measures (PHSM).
more
For humanitarian organisations to respond effectively to complex crises, they require access to up-to-date evidence-based guidance. The COVID-19 crisis has highlighted the importance of updating global guidance to context-specific and evolving needs in humanitarian settings. Our study aimed to under...stand the use of evidence-based guidance in humanitarian responses during COVID-19. Primary data collected during the rapidly evolving pandemic sheds new light on evidence-use processes in humanitarian response.
more
Nature | Vol 600 | 2 December 2021 |
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of a...cute COVID-19. It also includes advice on organising services for long COVID.
Updated 11 November 2021
more
La OMS ha elaborado una definición de caso clínico de la afección posterior a la COVID-19 mediante la metodología Delphi que incluye 12 dominios, disponible para su uso en todos los entornos. Esta primera versión fue elaborada por pacientes, investigadores y otras personas, en representación d...e todas las regiones de la OMS, en el entendimiento de que la definición puede cambiar a medida que surjan nuevas pruebas y siga evolucionando nuestra comprensión de las consecuencias de la COVID-19.
La afección posterior a la COVID-19 se produce en personas con antecedentes de infección probable o confirmada por el CoV-2 del SRAS, normalmente a los 3 meses de la aparición de la COVID-19 con síntomas y que duran al menos 2 meses y no pueden explicarse por un diagnóstico alternativo. Los síntomas más comunes son la fatiga, la dificultad respiratoria y la disfunción cognitiva, pero también otros, y generalmente tienen un impacto en el funcionamiento diario. Los síntomas pueden ser de nueva aparición tras la recuperación inicial de un episodio agudo de COVID-19 o persistir desde la enfermedad inicial. Los síntomas también pueden fluctuar o recaer con el tiempo.
more